Product Pathways - Growth Factors/Cytokines
Mouse Granulocyte Macrophage Colony Stimulating Factor (mGM-CSF) #5191
|5191LC||50 µg (With Carrier)||---||In Stock||---|
|5191LF||50 µg (Carrier Free)||---||In Stock||---|
|5191SF||10 µg (Carrier Free)||---||In Stock||---|
|5191SC||10 µg (With Carrier)||---||In Stock||---|
Already purchased this product? Write a Review.
Recombinant mouse GM-CSF (mGM-CSF) Ala18-Lys141 (Accession #NP_034099) was expressed in human 293 cells at Cell Signaling Technology.
Recombinant mGM-CSF contains no "tags" and the nonglycosylated protein has a calculated MW of 14,112.1. DTT-reduced protein migrates as a 22 kDa polypeptide and non-reduced protein migrates as a 19 kDa polypeptide due to intramolecular cystines. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino-terminal APTRS of recombinant mGM-CSF was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mGM-CSF. All lots are greater than 98% pure.
The bioactivity of recombinant mGM-CSF was determined in a MC/9 cell proliferation assay. The ED50 of each lot is between 6-25 pg/ml.
The purity of recombinant mGM-CSF was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mGM-CSF and staining overnight with Coomassie Blue.
The proliferation of MC/9 cells treated with increasing concentrations of mGM-CSF was assessed. After 48 hour treatment with mGM-CSF, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.
Western blot analysis of extracts from MC/9 cells untreated or treated with mGM-CSF for 10 minutes, using Phospho-Stat5 (Tyr694) (C11C5) Rabbit mAb #9359 (upper) and Stat5 (3H7) Rabbit mAb #9358 (lower).
Less than 0.01 ng endotoxin/1μg mGM-CSF.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg mGM-CSF. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
GM-CSF is produced by activated T cells, NK cells and macrophages (1,2). Target cells include granulocytes, monocyte precursors and subsets of differentiated myeloid cells (1,3,4). Many target cells require GM-CSF for survival. GM-CSF induces proliferation, is involved in the hematopoietic differentiation of dendritic cells and is a key factor in differentiation pathways leading from stem cells. GM-CSF activates effector functions of myeloid cells, thereby linking adaptive and innate immunity and in turn may boost anti-tumor immunity (5). GM-CSF receptor is composed of GM-CSFRα and the common β chain, βC, which is also utilized by IL-3 and IL-5 (1). Binding of GM-CSF initiates the Jak2, Stat5 and PI3K/Akt pathways (1).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.